Aspen Pharmacare Holdings Limited

DB:LDZA Stock Report

Market Cap: €4.0b

Aspen Pharmacare Holdings Past Earnings Performance

Past criteria checks 1/6

Aspen Pharmacare Holdings has been growing earnings at an average annual rate of 16.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 4.6% per year. Aspen Pharmacare Holdings's return on equity is 5.2%, and it has net margins of 9.9%.

Key information

16.8%

Earnings growth rate

17.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate4.6%
Return on equity5.2%
Net Margin9.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aspen Pharmacare Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:LDZA Revenue, expenses and earnings (ZAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2444,7064,40410,1000
31 Mar 2443,7034,6369,9360
31 Dec 2342,7004,8689,7710
30 Sep 2341,7055,0489,5830
30 Jun 2340,7095,2289,3940
31 Mar 2339,5425,5159,1270
31 Dec 2238,3755,8028,8590
30 Sep 2238,4916,1458,6920
30 Jun 2238,6066,4888,5250
31 Mar 2238,5606,1858,6560
31 Dec 2138,5145,8818,7960
30 Sep 2138,1405,3408,9550
30 Jun 2137,7664,7989,1140
31 Mar 2135,7603,9548,8660
31 Dec 2036,3083,7829,0750
30 Sep 2034,9843,5818,9760
30 Jun 2033,6593,3808,8760
31 Mar 2039,9273,2729,9880
31 Dec 1933,6208708,9540
30 Sep 1934,5671,2759,1540
30 Jun 1935,5141,6799,3540
31 Mar 1936,8803,3509,6120
31 Dec 1836,6834,8909,5750
30 Sep 1837,4995,2569,5730
30 Jun 1838,3145,6219,5700
31 Mar 1839,6185,6829,6780
31 Dec 1740,9225,7439,7860
30 Sep 1741,0685,4369,6360
30 Jun 1741,2135,1289,4850
31 Mar 1739,5574,4149,2930
31 Dec 1637,9003,7009,1000
30 Sep 1636,7504,0008,8500
30 Jun 1635,6004,3008,6000
31 Mar 1635,5835,2208,5530
31 Dec 1535,5676,1408,5060
30 Sep 1535,8335,6708,5030
30 Jun 1536,1005,2008,5000
31 Mar 1535,8365,3698,0710
31 Dec 1435,5725,5377,6410
30 Sep 1432,5445,2726,8470
30 Jun 1429,5155,0086,0540
31 Mar 1425,9014,3885,2000
31 Dec 1322,2873,7684,3460

Quality Earnings: LDZA has a large one-off loss of ZAR1.9B impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: LDZA's current net profit margins (9.9%) are lower than last year (12.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LDZA's earnings have grown by 16.8% per year over the past 5 years.

Accelerating Growth: LDZA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: LDZA had negative earnings growth (-15.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).

Return on Equity

High ROE: LDZA's Return on Equity (5.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre BekkerArqaam Capital Research Offshore S.A.L.
Boitshepo SeruweAvior Capital Markets
Simon MatherBarclays